RU2016144908A - Маркеры hdl-терапии - Google Patents
Маркеры hdl-терапии Download PDFInfo
- Publication number
- RU2016144908A RU2016144908A RU2016144908A RU2016144908A RU2016144908A RU 2016144908 A RU2016144908 A RU 2016144908A RU 2016144908 A RU2016144908 A RU 2016144908A RU 2016144908 A RU2016144908 A RU 2016144908A RU 2016144908 A RU2016144908 A RU 2016144908A
- Authority
- RU
- Russia
- Prior art keywords
- hdl
- therapeutic agent
- use according
- subject
- dose
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title claims 9
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 158
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 158
- 239000003814 drug Substances 0.000 claims 137
- 229940124597 therapeutic agent Drugs 0.000 claims 135
- 238000000034 method Methods 0.000 claims 20
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 16
- 210000002540 macrophage Anatomy 0.000 claims 10
- 210000001616 monocyte Anatomy 0.000 claims 10
- 210000005087 mononuclear cell Anatomy 0.000 claims 10
- 230000035772 mutation Effects 0.000 claims 9
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 claims 8
- 235000012000 cholesterol Nutrition 0.000 claims 8
- 102100026839 Sterol regulatory element-binding protein 1 Human genes 0.000 claims 7
- 108010002025 CER-001 Proteins 0.000 claims 6
- 230000006698 induction Effects 0.000 claims 6
- 238000012423 maintenance Methods 0.000 claims 6
- 102000004895 Lipoproteins Human genes 0.000 claims 5
- 108090001030 Lipoproteins Proteins 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 238000001802 infusion Methods 0.000 claims 4
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 3
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 3
- 108010071619 Apolipoproteins Proteins 0.000 claims 3
- 102000007592 Apolipoproteins Human genes 0.000 claims 3
- 231100000673 dose–response relationship Toxicity 0.000 claims 3
- 239000003550 marker Substances 0.000 claims 3
- 108020004999 messenger RNA Proteins 0.000 claims 3
- 239000000816 peptidomimetic Substances 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 150000003384 small molecules Chemical group 0.000 claims 3
- 108010087614 Apolipoprotein A-II Proteins 0.000 claims 2
- 102000009081 Apolipoprotein A-II Human genes 0.000 claims 2
- 102100037320 Apolipoprotein A-IV Human genes 0.000 claims 2
- 102000013918 Apolipoproteins E Human genes 0.000 claims 2
- 108010025628 Apolipoproteins E Proteins 0.000 claims 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- 102000014190 Phosphatidylcholine-sterol O-acyltransferase Human genes 0.000 claims 2
- 108010011964 Phosphatidylcholine-sterol O-acyltransferase Proteins 0.000 claims 2
- 108010073614 apolipoprotein A-IV Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 claims 2
- 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 claims 2
- 230000002950 deficient Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 229960000815 ezetimibe Drugs 0.000 claims 2
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 230000001483 mobilizing effect Effects 0.000 claims 2
- 229960003512 nicotinic acid Drugs 0.000 claims 2
- 235000001968 nicotinic acid Nutrition 0.000 claims 2
- 239000011664 nicotinic acid Substances 0.000 claims 2
- 230000003319 supportive effect Effects 0.000 claims 2
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 claims 1
- 102000055510 ATP Binding Cassette Transporter 1 Human genes 0.000 claims 1
- 108700005241 ATP Binding Cassette Transporter 1 Proteins 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- 108010057973 CSL-111 Proteins 0.000 claims 1
- -1 CSL-112 Proteins 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 108010078791 Carrier Proteins Proteins 0.000 claims 1
- 108010016695 ETC216 Proteins 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 102000013010 Member 1 Subfamily G ATP Binding Cassette Transporter Human genes 0.000 claims 1
- 108010090314 Member 1 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 claims 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 1
- 229940122392 PCSK9 inhibitor Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 1
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims 1
- 101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- 108010022999 Serine Proteases Proteins 0.000 claims 1
- 102000012479 Serine Proteases Human genes 0.000 claims 1
- 102000008078 Sterol Regulatory Element Binding Protein 1 Human genes 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 229920000080 bile acid sequestrant Polymers 0.000 claims 1
- 150000001840 cholesterol esters Chemical class 0.000 claims 1
- 230000003203 everyday effect Effects 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 208000029498 hypoalphalipoproteinemia Diseases 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 150000002948 pantothenic acids Chemical class 0.000 claims 1
- 229960002965 pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- 208000032666 primary 1 hypoalphalipoproteinemia Diseases 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Marine Sciences & Fisheries (AREA)
- Endocrinology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461988095P | 2014-05-02 | 2014-05-02 | |
| US61/988,095 | 2014-05-02 | ||
| PCT/IB2015/000854 WO2015173633A2 (en) | 2014-05-02 | 2015-04-30 | Hdl therapy markers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016144908A true RU2016144908A (ru) | 2018-06-05 |
| RU2016144908A3 RU2016144908A3 (enExample) | 2018-12-18 |
Family
ID=54147231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016144908A RU2016144908A (ru) | 2014-05-02 | 2015-04-30 | Маркеры hdl-терапии |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20150316566A1 (enExample) |
| EP (1) | EP3137899A2 (enExample) |
| JP (1) | JP2017515893A (enExample) |
| KR (1) | KR20170003611A (enExample) |
| CN (1) | CN106488987A (enExample) |
| AU (1) | AU2015260929A1 (enExample) |
| BR (1) | BR112016025470A2 (enExample) |
| CA (1) | CA2947127A1 (enExample) |
| IL (1) | IL248601A0 (enExample) |
| MX (1) | MX2016014306A (enExample) |
| PH (1) | PH12016502167A1 (enExample) |
| RU (1) | RU2016144908A (enExample) |
| SG (1) | SG11201609084QA (enExample) |
| WO (1) | WO2015173633A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3464613A4 (en) * | 2016-05-31 | 2020-01-08 | Institut de Cardiologie de Montréal | CO-CULTURE SYSTEM AND METHOD FOR IN-VITRO EVALUATION OF CHOLESTERIN RETURN |
| WO2018029505A1 (en) | 2016-08-11 | 2018-02-15 | Cerenis Therapeutics Holding Sa | Cer-001 therapy for treating familial primary hypoalphalipoproteinemia |
| ES2681124B1 (es) * | 2017-03-08 | 2019-06-19 | Fund Imdea Alimentacion | Usos medicos de la apolipoproteina a y de activadores de la misma |
| CN108913761B (zh) * | 2017-08-10 | 2022-01-18 | 施军平 | 一种用于筛查遗传性肝病的试剂盒 |
| WO2019043201A1 (en) * | 2017-09-01 | 2019-03-07 | Sorbonne Universite | TRANSCRIPTION FACTOR ZNF471 USED AS THERAPEUTIC AGENT AND BIOMARKER |
| CN107764890B (zh) * | 2017-10-16 | 2019-12-17 | 杭州先导医药科技有限责任公司 | 一种依折麦布对映异构体的区分检测方法 |
| WO2020185598A1 (en) * | 2019-03-08 | 2020-09-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for assessing cardiovascular disease or inflammatory disease risk using non-exchangeable lipid probe |
| CN112442114A (zh) * | 2019-08-29 | 2021-03-05 | 渥太华Hdl药物研发公司 | 一种多肽及其应用 |
| EP4135747A1 (en) | 2020-04-16 | 2023-02-22 | Abionyx Pharma SA | Methods for treating acute conditions using lipid binding protein- based complexes |
| WO2021209808A1 (en) * | 2020-04-16 | 2021-10-21 | Abionyx Pharma Sa | Cer-001 therapy for treating kidney disease |
| CN115666720A (zh) | 2020-04-16 | 2023-01-31 | 阿比奥尼克斯制药公司 | 用于治疗肾病的cer-001疗法 |
| KR20230057410A (ko) | 2020-08-25 | 2023-04-28 | 리제너론 파마슈티칼스 인코포레이티드 | Pcsk9 및 ldlr 조절인자를 사용한 패혈증 치료 |
| JP2023543498A (ja) | 2020-10-01 | 2023-10-16 | アビオニクス ファーマ エスエー | 脂質結合タンパク質ベースの複合体を使用した、眼疾患を治療するための方法 |
| JP2023553609A (ja) * | 2020-12-11 | 2023-12-25 | ヘルシンギン ユリオピスト | 対象が脂質低下療法に応答する可能性を判定する方法 |
| JP2024514154A (ja) | 2021-04-15 | 2024-03-28 | アビオニクス ファーマ エスエー | 臓器保存溶液における脂質結合タンパク質ベースの複合体の使用 |
| CN113332423A (zh) * | 2021-05-26 | 2021-09-03 | 华中科技大学同济医学院附属协和医院 | 一种pcsk9抑制剂在心脏移植术后抗排斥反应中的应用 |
| EP4504233A1 (en) | 2022-04-06 | 2025-02-12 | Abionyx Pharma SA | Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes |
| EP4504150A1 (en) | 2022-04-06 | 2025-02-12 | Abionyx Pharma SA | Methods for treating eye diseases using lipid binding protein-based complexes |
| CN120344255A (zh) | 2022-06-10 | 2025-07-18 | 阿比奥尼克斯制药公司 | 使用基于脂质结合蛋白的复合物治疗过度炎性病症的方法 |
| EP4536269A2 (en) | 2022-06-10 | 2025-04-16 | Abionyx Pharma SA | Methods for treating acute conditions using lipid binding protein-based complexes |
| AU2024207875A1 (en) | 2023-01-13 | 2025-07-24 | Abionyx Pharma Sa | Lipid binding protein molecule therapy |
| WO2025093929A1 (en) | 2023-10-31 | 2025-05-08 | Abionyx Pharma Sa | Lipid binding protein molecule therapy |
| CN119534676B (zh) * | 2024-10-15 | 2025-08-15 | 中日友好医院(中日友好临床医学研究所) | 代谢标志物在制备监测pb神经毒性产品中的应用及制品 |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8712540D0 (en) | 1987-05-28 | 1987-07-01 | Ucb Sa | Expression of human proapolipoprotein a-i |
| US5220043A (en) | 1991-03-21 | 1993-06-15 | Ohio University | Synthesis of D-erythro-sphingomyelins |
| SE9103701D0 (sv) | 1991-12-13 | 1991-12-13 | Kabi Pharmacia Ab | Apolipoprotein |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| SE9203753D0 (sv) | 1992-12-11 | 1992-12-11 | Kabi Pharmacia Ab | Expression system for producing apolipoprotein ai-m |
| FR2704556B1 (fr) | 1993-04-30 | 1995-07-13 | Rhone Poulenc Rorer Sa | Virus recombinants et leur utilisation en thérapie génique. |
| JP3754072B2 (ja) | 1994-03-22 | 2006-03-08 | リサーチ・コーポレーション・テクノロジーズ・インコーポレーテッド | 摂食抑制ペプチド |
| US5932536A (en) | 1994-06-14 | 1999-08-03 | The Rockefeller University | Compositions for neutralization of lipopolysaccharides |
| SE9500778D0 (sv) | 1995-03-03 | 1995-03-03 | Pharmacia Ab | Process for producing a protein |
| US5648387A (en) | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
| US6258596B1 (en) | 1995-05-22 | 2001-07-10 | Aventis Pharmaceuticals Products Inc. | Variants of apolipoprotein A-I |
| GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| SE9603068D0 (sv) | 1996-08-23 | 1996-08-23 | Pharmacia & Upjohn Ab | Process for purifying a protein |
| SE9603303D0 (sv) | 1996-09-11 | 1996-09-11 | Pharmacia & Upjohn Ab | Process for purifying a protein |
| SE9603304D0 (sv) | 1996-09-11 | 1996-09-11 | Pharmacia & Upjohn Ab | Process for purifying a compound |
| US6306433B1 (en) | 1997-08-12 | 2001-10-23 | Pharmacia Ab | Method of preparing pharmaceutical compositions |
| US6518412B1 (en) | 1997-09-29 | 2003-02-11 | Jean-Louis Dasseux | Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6046166A (en) | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6037323A (en) | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6287590B1 (en) | 1997-10-02 | 2001-09-11 | Esperion Therapeutics, Inc. | Peptide/lipid complex formation by co-lyophilization |
| US6454950B1 (en) | 1998-12-30 | 2002-09-24 | Amersham Pharmacia Biotech Ab | Separation method utilizing liquid-liquid partition |
| CN1329359C (zh) | 1999-04-01 | 2007-08-01 | 埃斯佩里安医疗公司 | 醚化合物,及其组合物和用途 |
| GB9919713D0 (en) | 1999-08-19 | 1999-10-20 | Queen Mary & Westfield College | New medical use of high density lipoprotein |
| CA2405550A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US6946134B1 (en) | 2000-04-12 | 2005-09-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| PT1290013E (pt) | 2000-04-21 | 2006-06-30 | Amgen Inc | Derivados dos peptidos apo-ai/aii |
| US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
| US7148197B2 (en) | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| US6664230B1 (en) | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US7166578B2 (en) | 2000-08-24 | 2007-01-23 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US7144862B2 (en) | 2000-08-24 | 2006-12-05 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US7199102B2 (en) | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US7723303B2 (en) | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| US7304093B2 (en) | 2000-10-11 | 2007-12-04 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
| JP2004531459A (ja) | 2000-10-11 | 2004-10-14 | エスペリオン セラピューティクス，インコーポレイテッド | コレステロールマネージメント用スルホキシドおよびビススルホキシド化合物ならびに組成物および関連する使用 |
| JP2004532799A (ja) | 2000-10-11 | 2004-10-28 | エスペリオン セラピューティクス，インコーポレイテッド | コレステロール管理および関連用途のためのスルフィド化合物およびジスルフィド化合物ならびにそれらを含む組成物 |
| MXPA03003021A (es) | 2000-10-11 | 2003-07-14 | Esperion Therapeutics Inc | Compuestos de eter y composiciones para el control del colesterol y usos relacionados. |
| CN1283610C (zh) | 2000-10-11 | 2006-11-08 | 埃斯佩里安医疗公司 | 用于控制胆固醇以及相关用途的酮化合物以及组合物 |
| WO2002038609A2 (en) | 2000-11-10 | 2002-05-16 | Proteopharma Aps | Apolipoprotein conjugates |
| US7507413B2 (en) | 2001-04-12 | 2009-03-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7217785B2 (en) | 2001-05-09 | 2007-05-15 | The Regents Of The University Of California | Cysteine-containing peptides having antioxidant properties |
| US20060060520A1 (en) | 2001-06-25 | 2006-03-23 | Bomberger David C | Systems and methods using a solvent for the removal of lipids from fluids |
| US6991727B2 (en) | 2001-06-25 | 2006-01-31 | Lipid Sciences, Inc. | Hollow fiber contactor systems for removal of lipids from fluids |
| AU2002322284A1 (en) | 2001-06-25 | 2003-01-08 | Lipid Sciences, Inc. | Systems and methods using multiple solvents for the removal of lipids from fluids |
| CA2457840C (en) | 2001-08-20 | 2011-10-11 | Zlb Bioplasma Ag | Hdl for the treatment of stroke and other ischemic conditions |
| CA2460787A1 (en) | 2001-09-28 | 2003-04-03 | Esperion Therapeutics, Inc. | Prevention and treatment of restenosis by local administration of drug |
| AUPR798901A0 (en) | 2001-09-28 | 2001-10-25 | Medvet Science Pty. Ltd. | Spheroidal hdl particles with a defined phospholipid composition |
| AU2002364586A1 (en) | 2001-12-21 | 2003-07-30 | Delta Biotechnology Limited | Albumin fusion proteins |
| US7223726B2 (en) | 2002-01-14 | 2007-05-29 | The Regents Of The University Of California | Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same |
| US6930085B2 (en) | 2002-04-05 | 2005-08-16 | The Regents Of The University Of California | G-type peptides to ameliorate atherosclerosis |
| US7691965B2 (en) | 2002-05-08 | 2010-04-06 | The Regents Of The University Of California | Helical synthetic peptides that stimulate cellular cholesterol efflux |
| BR0310099A (pt) | 2002-05-17 | 2007-03-20 | Esperion Therapeutics Inc | método para tratar dislipidemia ou uma doença associada com a dislipidemia |
| WO2004010939A2 (en) | 2002-07-30 | 2004-02-05 | Esperion Therapeutics, Inc. | Methods of using non-human animal apoliprotein a-i protein |
| CA2513213C (en) | 2003-01-22 | 2013-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| JP4931349B2 (ja) | 2003-01-23 | 2012-05-16 | エスペリオン セラピューティクス，インコーポレイテッド | コレステロール管理およびそれに関連した使用に供するヒドロキシル化合物および組成物 |
| PT1641421T (pt) | 2003-07-03 | 2019-03-27 | Hdl Therapeutics Inc | Métodos e dispositivos para criar derivados de partículas de hdl com conteúdo de lípidos reduzido |
| US7393826B2 (en) | 2003-07-03 | 2008-07-01 | Lipid Sciences, Inc. | Methods and apparatus for creating particle derivatives of HDL with reduced lipid content |
| CA2543596A1 (en) | 2003-11-07 | 2005-05-26 | Jj Pharma, Inc. | Hdl-boosting combination therapy complexes |
| TW200526778A (en) | 2003-11-14 | 2005-08-16 | Sembiosys Genetics Inc | Methods for the production of apolipoproteins in transgenic plants |
| US7781219B2 (en) | 2003-12-05 | 2010-08-24 | The Cleveland Clinic Foundation | Risk markers for cardiovascular disease |
| CA2549995C (en) | 2003-12-24 | 2011-11-15 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
| KR100560102B1 (ko) | 2004-06-25 | 2006-03-13 | 한국생명공학연구원 | 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제 |
| WO2006020498A2 (en) | 2004-08-11 | 2006-02-23 | The Cleveland Clinic Foundation | Therapeutic agents and methods for cardiovascular disease |
| AU2005295640B2 (en) | 2004-10-15 | 2011-07-28 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Multi-domain amphipathic helical peptides and methods of their use |
| US8206750B2 (en) | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
| US8163699B2 (en) | 2006-06-01 | 2012-04-24 | Montreal Heart Institute | Method for the treatment of valvular disease |
| EP2049137A4 (en) | 2006-08-08 | 2013-05-01 | Univ California | SALICYLANILIDES AS AMPLIFIERS OF THE ORAL RELEASE OF THERAPEUTIC PEPTIDES |
| US8541236B2 (en) | 2006-12-08 | 2013-09-24 | University Of Washington | Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls |
| DK2118074T3 (en) | 2007-02-01 | 2014-03-10 | Resverlogix Corp | Compounds for the prevention and treatment of cardiovascular diseases |
| US7956035B2 (en) | 2007-03-01 | 2011-06-07 | Csl Limited | Treatment of endothelial dysfunction in diabetic patients |
| US7749315B2 (en) | 2007-04-04 | 2010-07-06 | Xerox Corporation | Phase change inks containing colorant compounds |
| JP5600061B2 (ja) | 2007-08-17 | 2014-10-01 | ツェーエスエル ベーリンク ゲゼルシャフト ミット ベシュレンクテル ハフツング | α−１−抗トリプシンおよびアポリポタンパク質Ａ−Ｉを精製する方法 |
| JP2010537638A (ja) | 2007-08-28 | 2010-12-09 | ユーエービー リサーチ ファウンデーション | 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法 |
| US7985728B1 (en) | 2007-09-20 | 2011-07-26 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
| US8044021B2 (en) | 2007-09-20 | 2011-10-25 | Abbott Cardiovascular Systems Inc. | Sustained release of apo A-I mimetic peptides and methods of treatment |
| US8101565B2 (en) | 2007-09-20 | 2012-01-24 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
| US7985727B1 (en) | 2007-09-20 | 2011-07-26 | Abbott Cardiovascular Systems Inc. | Apo A-I mimetic peptides and methods of treatment |
| US8343932B2 (en) | 2007-10-19 | 2013-01-01 | Pronota N.V. | Protease-sensitive site in apolipoprotein A1, therapeutic and diagnostic implications |
| BRPI0818881A2 (pt) | 2007-10-23 | 2015-05-05 | Cleveland Clinic Foundation | Polipetídeo purificado, composição farmacêutica e métodos de de tratar distúrbios cardiovasculares, de promover efluxo de colesterol a partir de uma célula, de melhorar um ou mais sintomas de uma condição inflamatória em um indivíduo, de mitigar perda de oxidante mpo de função de efluxo de colesterol e de tratar dano de célula endotelial em um indivíduo |
| RU2011101536A (ru) | 2008-06-18 | 2012-07-27 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа (Us) | Усовершенствованные пептидные медиаторы оттока холестерина |
| DK2396017T3 (en) | 2009-02-16 | 2015-09-14 | Cerenis Therapeutics Holding Sa | Apolipoprotein A-I-mimetika |
| KR20230098713A (ko) | 2009-06-10 | 2023-07-04 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| EP2517013A4 (en) * | 2009-12-23 | 2013-07-17 | Artery Therapeutics Inc | DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH DEFICIENT REVERSE CHOLESTER INTRANSPORT |
| WO2012000048A1 (en) | 2010-06-30 | 2012-01-05 | Csl Limited | A reconstituted high density lipoprotein formulation and production method thereof |
| HUE042314T2 (hu) * | 2011-02-07 | 2019-06-28 | Cerenis Therapeutics Holding Sa | Lipoprotein komplexek és azok gyártása és alkalmazásai |
-
2015
- 2015-04-30 MX MX2016014306A patent/MX2016014306A/es unknown
- 2015-04-30 CA CA2947127A patent/CA2947127A1/en not_active Abandoned
- 2015-04-30 RU RU2016144908A patent/RU2016144908A/ru not_active Application Discontinuation
- 2015-04-30 AU AU2015260929A patent/AU2015260929A1/en not_active Abandoned
- 2015-04-30 SG SG11201609084QA patent/SG11201609084QA/en unknown
- 2015-04-30 CN CN201580035131.6A patent/CN106488987A/zh active Pending
- 2015-04-30 WO PCT/IB2015/000854 patent/WO2015173633A2/en not_active Ceased
- 2015-04-30 US US14/700,351 patent/US20150316566A1/en not_active Abandoned
- 2015-04-30 KR KR1020167033725A patent/KR20170003611A/ko not_active Withdrawn
- 2015-04-30 EP EP15766230.5A patent/EP3137899A2/en not_active Withdrawn
- 2015-04-30 BR BR112016025470A patent/BR112016025470A2/pt not_active IP Right Cessation
- 2015-04-30 JP JP2017508775A patent/JP2017515893A/ja active Pending
-
2016
- 2016-10-30 IL IL248601A patent/IL248601A0/en unknown
- 2016-11-02 PH PH12016502167A patent/PH12016502167A1/en unknown
-
2018
- 2018-03-07 US US15/914,087 patent/US20180203025A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016025470A2 (pt) | 2017-08-15 |
| US20150316566A1 (en) | 2015-11-05 |
| KR20170003611A (ko) | 2017-01-09 |
| PH12016502167A1 (en) | 2017-01-09 |
| US20180203025A1 (en) | 2018-07-19 |
| EP3137899A2 (en) | 2017-03-08 |
| AU2015260929A1 (en) | 2016-12-15 |
| CA2947127A1 (en) | 2015-11-19 |
| IL248601A0 (en) | 2016-12-29 |
| SG11201609084QA (en) | 2016-11-29 |
| CN106488987A (zh) | 2017-03-08 |
| RU2016144908A3 (enExample) | 2018-12-18 |
| MX2016014306A (es) | 2017-06-12 |
| WO2015173633A3 (en) | 2016-01-21 |
| WO2015173633A2 (en) | 2015-11-19 |
| JP2017515893A (ja) | 2017-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016144908A (ru) | Маркеры hdl-терапии | |
| JP2017515893A5 (enExample) | ||
| Landlinger et al. | The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE* 3Leiden. CETP mice | |
| Tanaka et al. | RANKL: a therapeutic target for bone destruction in rheumatoid arthritis | |
| Liu et al. | Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau | |
| JP7295179B2 (ja) | Ｅｔｃ１００２及びエゼチミブを含む固定用量組合せ物及び製剤並びに心血管疾患を処置するか又は心血管疾患のリスクを低減させる方法 | |
| JP2016538277A5 (enExample) | ||
| JP2017528427A5 (enExample) | ||
| Mulder et al. | First clinical experiences with inclisiran in a real-world setting | |
| JP2018536710A5 (enExample) | ||
| RU2009139221A (ru) | Введение антисмысловых олигонуклеотидов, комплементарных человеческому аполипопротеину в | |
| RU2013139727A (ru) | Антитела человека к pcsk9 для применения в способах лечения конкретных групп индивидуумов | |
| EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| Sjouke et al. | Familial hypercholesterolemia: present and future management | |
| PH12014500472A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| PH12014500371A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| Geusens | Emerging treatments for postmenopausal osteoporosis–focus on denosumab | |
| Kerckhove et al. | Ethosuximide improves chronic pain-induced anxiety-and depression-like behaviors | |
| Di Bartolo et al. | PCSK9 inhibitors in hyperlipidemia: current status and clinical outlook | |
| Gundavarapu et al. | A critical role of acute bronchoconstriction in the mortality associated with high-dose sarin inhalation: effects of epinephrine and oxygen therapies | |
| Nicholls et al. | Lipid pharmacotherapy for treatment of atherosclerosis | |
| Bays et al. | Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading? | |
| Shen et al. | Population pharmacokinetics (PK) and pharmacodynamics (PD) analysis of LY3015014, a monoclonal antibody to protein convertase subtilisin/kexin type 9 (PCSK9) in healthy subjects and hypercholesterolemia patients | |
| Verdelli et al. | Drug induction in connective tissue diseases | |
| Kim et al. | Retrospective analysis of the financial break-even point for intrathecal morphine pump use in Korea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190408 |